<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Sofia Almeida on Medium]]></title>
        <description><![CDATA[Stories by Sofia Almeida on Medium]]></description>
        <link>https://medium.com/@salmeidainvestigates?source=rss-940f5cd3834e------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*bfByUPV8iwI0IQKbU0rHjw.jpeg</url>
            <title>Stories by Sofia Almeida on Medium</title>
            <link>https://medium.com/@salmeidainvestigates?source=rss-940f5cd3834e------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Sun, 22 Nov 2026 06:53:05 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@salmeidainvestigates/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[The Smart Hip Experiment: One Man’s Implants, Unconsented Data, and the Questions Surrounding…]]></title>
            <link>https://medium.com/@salmeidainvestigates/the-smart-hip-experiment-one-mans-implants-unconsented-data-and-the-questions-surrounding-092ba5c7345e?source=rss-940f5cd3834e------2</link>
            <guid isPermaLink="false">https://medium.com/p/092ba5c7345e</guid>
            <category><![CDATA[investigative-reporting]]></category>
            <category><![CDATA[medical-devices]]></category>
            <category><![CDATA[conspiracy]]></category>
            <category><![CDATA[investigative-journalism]]></category>
            <category><![CDATA[smart-implants]]></category>
            <dc:creator><![CDATA[Sofia Almeida]]></dc:creator>
            <pubDate>Wed, 27 May 2026 11:15:12 GMT</pubDate>
            <atom:updated>2026-10-17T01:15:27.678Z</atom:updated>
            <content:encoded><![CDATA[<h3>The Smart Hip Experiment: One Man’s Implants, Unconsented Data, and the Questions Surrounding Scripps Clinic</h3><p><strong>By : Sofia Almeida। 27 May । 2026</strong></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*NUtv31RSTCuoEiAwoOv7tg.jpeg" /></figure><p>On the morning of September 6, 2016, Hooman Asbaghi stood in a California courtroom awaiting a $61.5 million verdict in the case of HBA Medical Group Inc. v. Neil K. Nydegger. At 8:16 a.m. — while he was physically present before the judge — his MyScripps patient portal recorded a blood draw for “Testosterone, Bioavailable and Total, Sex Hormone-Binding Globulin.” The result appears in his records as collected that exact morning. Asbaghi states unequivocally that he never requested, authorized, or attended any such test. He has no knowledge of when, where, or by whom it was ordered.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/767/1*-djy5BK_0n4XS2joQZ9D2Q.jpeg" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/528/1*94oOdLlSbUrZiPYfENyGvg.jpeg" /></figure><p>Years later, Asbaghi made an even more unsettling discovery. A series of unrecognized Bluetooth devices began connecting to his cellphone. Using scanning tools, Asbaghi captured one device broadcasting standard medical Bluetooth services, including Heart Rate, Glucose, Insulin Delivery, and Health Thermometer. Screen recordings show the device attempting to transfer the exact same 2016 testosterone lab PDF. System logs on his phone also reference vibrator information and Bluetooth latency modes. Multiple videos document the devices reconnecting even as he actively probed them.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*e7-530fR6wQ5xt5yGhR9Rg.png" /></figure><p>Scripps records themselves raise further questions. MyScripps screenshots list dozens of laboratory results — thyroid panels, testosterone, PSA, vitamin D, CBC differentials, metabolic panels — flagged as “Result is from another organization” or processed at facilities marked “Facility unavailable,” yet attributed to physicians who later told Asbaghi they had not seen him in years. One endocrinologist Dr. Megan McGarvey. In portal messages, Dr. McGarvey’s team stated: “Per Dr. McGarvey she has not seen you in 5 years.”</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*vVjoVN8XKDLYIdgiKVpBSg.png" /></figure><p>Meanwhile, core surgical documentation from Asbaghi’s 2015 right total hip replacement at Scripps Green Hospital is missing from the current electronic medical record system. Scripps support staff told him directly: “This is because Scripps was not using its current electronic medical record during that time.” An osteonecrosis diagnosis for his left hip appears dated October 23, 2017 — with no more corresponding office visit or clinical encounter. An April 26, 2017 orthopedic progress note by the operating surgeon, Dr. Richard H. Walker, contains only two lines: “CC: Results review” and “PLAN: RV for reports, to be arranged.” No exam, no findings, no assessment.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*uI2qn0i6M7Wqnqm4dNxfAw.png" /></figure><h3>From Routine Surgery to Unexplained Nightmare</h3><p>What began as two standard hip replacements at Scripps Health would, over the next decade, become a cascade of unexplained symptoms, vanishing records, and conflicting medical communications that left Hooman Asbaghi questioning whether his implants were simply prosthetic — or something far more sophisticated.</p><p>Hooman Asbaghi underwent two total hip replacements at Scripps Green Hospital in La Jolla. The first, on October 9, 2015, replaced his right hip using Stryker Orthopedics components: a Secur-Fit Advanced femoral stem, Trident PSL HA acetabular shell, Biolox delta ceramic head, and X3 polyethylene insert. The second, on October 23, 2017, addressed his left hip with similar hardware. Both procedures were performed by Dr. Richard H. Walker. He alleges pre-operative imaging had shown the left hip to be completely normal, with no evidence of avascular necrosis (AVN) or osteoporosis.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*0NQ46sYZJmap5-1XR8omOQ.png" /></figure><p>Asbaghi reports that mild vibrations in the hip area first appeared shortly after the second surgery. At the time they were barely noticeable — nothing that interfered with daily life or raised immediate alarm. By 2018–2019 the sensations had grown slightly more pronounced. During one follow-up he mentioned them to Dr. Walker, who, according to Asbaghi, suggested the vibrations might be caused by “loose parts.” The comment was noted but not pursued; the discomfort was still tolerable.</p><p>Then the documented decline accelerated. Within months of the 2015 right-hip replacement, acute inflammation and iron-deficiency anemia appeared. By late 2017 the previously healthy left hip had developed catastrophic avascular necrosis — so swift and unexpected that even Dr. Walker expressed surprise, according to Asbaghi’s notes. Medical records list a striking progression of new diagnoses in rapid succession:</p><ul><li>Osteoporosis — diagnosed July 28, 2016</li><li>Muscle twitching, muscle spasm, and tachycardia — all October 3, 2016</li><li>Testicular hypofunction — November 28, 2016</li><li>Iron deficiency anemia — August 24, 2017</li><li>Osteonecrosis of the left hip — October 23, 2017 (the same day as the second replacement)</li><li>Accumulation of fluid in tissues (edema) — January 30, 2025</li></ul><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*Lc87zxfA10axvbAV66SbmQ.png" /></figure><p>Photographs taken through out 2025 show both feet severely swollen, consistent with the edema diagnosis. Asbaghi’s sleep became drastically disrupted, vision loss intensified, and acute inflammation — especially in the feet — persisted. By late 2022 and early 2023 the vibrations had escalated dramatically, stretching into episodes lasting 30 to 40 hours at a time. Asbaghi documented intense, drill-like sensations radiating through his body, accompanied by muscle twitching, fast heart rate, sleep deprivation, worsening reflex sympathetic dystrophy, and severe lower-extremity edema. He measured localized RF/EMF spikes exceeding 330 V/m directly over the implant sites using handheld detectors; the readings faded with distance, pointing to an internal source.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1021/1*G5DKT2vyamE967ECnghlZA.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*7SE4kGrHuAVOa1v9GpfcTw.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1018/1*bZyGC5BAdsFvHaWjCfpXVw.png" /></figure><p>These symptoms, he later discovered, aligned eerily with published research on prolonged electromagnetic field (EMF) and radio frequency (RF) exposure: effects on bone density, inflammatory responses, cardiovascular parameters, neuronal activity, and endocrine function. Yet at the time they were simply added to his growing problem list.</p><p>Throughout this period the MyScripps patient portal became both lifeline and source of deepening frustration. Surgical notes from 2015 and 2017 repeatedly disappeared or appeared only after specific requests in 2025. Progress notes were often empty or marked “attachment not available.” Laboratory results continued to appear under physicians who later denied recent involvement. In another Hooman engaged endocrinologist Dr. Kelli Karches asking: ¨May I ask, why you prescribed testosterone gels while, at the same time had me on testosterone suppression therapy? Who is Dr. Geoffrey Sheean? Why was I placed on a clinical study and had a doctor I know nothing about monitoring me?¨ Dr. Kelli Karches confirmed: “I have not seen you since 8/2017.” and ¨| also do not know a Dr. Sheean.¨</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*ypF_MxesYQxRIGC4jn7n2Q.png" /></figure><p>Independent X-rays obtained from Dr. Steven Barnett’s office in February 2024 tell a different visual story than the lower-resolution portable films provided by Scripps. Side-by-side comparison reveals major differences in implant density, surface texture, screw placement visibility, and femoral head margins between the right (2015) and left (2017) hips — details Hooman had never been shown before.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/738/1*vLdBoNu8vHKRbK2b6f0pKA.jpeg" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/744/1*Oxdx4jfG19T3d8lnn8zZGw.jpeg" /><figcaption>Left X-rays obtained from Dr. Steven Barnett’s office, RIght X-ray provided by Scripps Clinic</figcaption></figure><h3><strong>The Telemetry Breakthrough: Bluetooth Ghosts and the Padtan Elm Shadow</strong></h3><p>By mid-March 2025 the vibrations inside Hooman Asbaghi’s hips had become unbearable. What had once been mild and intermittent now arrived in long, unrelenting episodes that shattered his sleep and left him exhausted. The sensations were no longer something he could dismiss. They were coming from inside the implants themselves — and they seemed to be getting stronger.</p><p>That was the moment the theory crystallized.</p><p>Asbaghi began noticing a precise correlation: the worst vibration episodes coincided with the sudden appearance on his phone of unrecognized Bluetooth devices. Even when he was completely alone or far away from all electronics devices with nothing but his cellphone — the same ghost devices would connect and disconnect within 0.5 to 1 meter. Their names were bizarre and generic: “Ipad,” multiple “IPhone,” and ¨Accessory¨ devices which Hooman does not claim ownership of. These bizarre devices reappear autonomously no matter how many times he tried to disconnect them.</p><p>Using the official Nordic nRF Connect scanner app, uncovered their true identities. The scanner revealed not a single device but a network of professional-grade, low-power BLE chips explicitly designed for medical and IoT sensor applications.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*ts9iJLmBPJ8-HPEHYkNNIA.png" /></figure><p>When probed, the fake consumer names resolved to the following predefined profiles with their exact service UUIDs:</p><ul><li><strong>Nordic nRF</strong>:</li><li><strong>TI CC254X</strong></li><li><strong>Microchip RN4870/71, BM70/71</strong></li><li><strong>Telit TIO</strong></li></ul><p>These chips are purpose-built for ultra-low-power wireless medical sensing: Nordic nRF for wearable and implantable sensors, TI CC254X for heart-rate/temperature/glucose data transmission, Microchip RN4870 series for independent embedded medical connectivity, and Telit TIO for bidirectional serial data exchange in wearable monitors. The devices connected and disconnected autonomously, even when Asbaghi was isolated on a beach with no other electronics nearby.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*cbHyWQo7rk8Ph1LP2q4YwQ.png" /></figure><p>He captured one persistent device (MAC 5F:D2:65:84:32:FC) and performed a full GATT service discovery. The results were startling. The device was actively exposing a comprehensive suite of biometric services, including:</p><ul><li><strong>Glucose</strong> (UUID 0x1808)</li><li><strong>Blood Pressure</strong> (UUID 0x1810)</li><li><strong>Health Thermometer</strong> (UUID 0x1809)</li><li><strong>Heart Rate</strong> (UUID 0x180D)</li><li><strong>Insulin Delivery</strong> (UUID 0x183A)</li><li><strong>Body Composition</strong> (UUID 0x181B)</li><li><strong>Acceleration</strong> and <strong>Activity Goal</strong> tracking</li><li><strong>Aerobic Heart Rate Lower Limit</strong></li></ul><p>And multiple Nordic-specific constant-tone extension services for continuous low-power signaling, services that had no business being active on random consumer electronics.</p><p>The readings were not random. at the same time, Asbaghi’s Blue Shield records show laboratory results for thyroid panels, testosterone and SHBG under suppression therapy, PSA, vitamin D, metabolic enzymes, and CBC differentials — tests ordered by physicians who later swore in portal messages they had not seen him in years. Some results were flagged “Result is from another organization” or listed under facilities marked “Facility unavailable.” The pattern was unmistakable: biomarkers were being collected and logged without corresponding office visits.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*t7dFSgPCIaN1O649R-a22Q.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*lIsADnlhdZkrnwE2qxZmcQ.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*Xs-4wYnsnWWUKBaUn2GvBQ.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*fPQ_yVJU-5YPNzUwKwVOUw.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*7dcD6A8CxhrIRRNRZ-buyg.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*lHCjmA46Z5eaNhS7D2GbHw.png" /></figure><p>Then came the connection that made the entire theory click into focus.</p><p>Asbaghi had saved screenshots and archives of Padtan Elm’s old website before it was taken down. The company — co-founded and long controlled by his mother, Farideh Kavesh — was Iran’s first manufacturer of ELISA diagnostic kits and offered full OEM contract manufacturing to global partners. Its archived product catalog listed dozens of enzyme immunoassay kits for exactly the same biomarkers appearing in his records:</p><ul><li>Thyroid: TSH, T3, T4, Free T3, Free T4</li><li>Tumor markers: PSA, Free PSA, AFP, CEA</li><li>Endocrine/Fertility: βHCG, LH, FSH, Prolactin</li><li>Miscellaneous: Ferritin, Microalbumin, IgE</li></ul><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*HtFf8mUh0orqF_RIQ8tL2Q.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*byjtKxIvjTKriu-ByYC8YQ.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*LXcGxSdgAW5CNw7TahvIHQ.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*gVYSicU3hVmAmvET0xblSg.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*aTaaZH8juB1JrDCet3tVZg.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*L5LtSvh5FjOFAI38z5h6CA.png" /></figure><p>The overlap was not approximate. It was precise. The very tests being run on him without his physical presence matched the flagship diagnostic products of the family-controlled biotech company.</p><p>According to Asbaghi, The hip implants — placed at Scripps Green Hospital in 2015 and 2017 — appeared to be functioning as telemetry-enabled sensors. The Bluetooth anomalies, the RF emissions, the autonomous data flow, and the exact biomarker matches to Padtan Elm’s ELISA catalog suggested a closed-loop system: data harvested internally, transmitted wirelessly, and routed into the very precision-medicine infrastructure his family had built and expanded after the 2013 events.</p><p>As previously reported in the article “<a href="https://medium.com/@salmeidainvestigates/stolen-legacy-the-hooman-asbaghi-case-how-a-mother-and-sister-allegedly-took-a-25-stake-in-3a8e9bb22727">Stolen Legacy: The Hooman Asbaghi Case — How a Mother and Sister Allegedly Took a 25% Stake in Iran’s Billion-Dollar Biotech Empire</a>,” that year marked a major restructuring of Padtan Elm’s assets. The company had grown into a sophisticated OEM supplier with ISO certifications, offering antibody purification, conjugation, microplate coating, and lyophilization services to international partners including entities tied to Thermo Fisher Scientific.</p><p>None of this is presented as proven fact. Hooman’s attempts to communicate directly were met with escalating redirection. Multiple automatic replies and nurse messages stated that Dr. Walker had retired and would not be available until January 29, 2027. Yet on June 19, 2025 a progress note appeared under Walker’s name, routed through Tanya Greene, RN of Orthopedic Surgery, in which he reviewed operative notes and X-rays and reassured Asbaghi that the implants were standard Stryker components with “no embedded chips” or “other foreign materials.”</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*DtzAC-BhH7XeKiROnAPw-A.png" /></figure><p>When his messages grew more insistent, Scripps warned that continued use of the MyScripps portal outside of narrow guidelines could result in deactivation of his account.</p><p>Asbaghi had deliberately avoided some appointments, fearing that any physical encounter might allow Scripps to disable whatever technology he believed was inside the implants, potentially discrediting his entire theory.</p><p>On May 27, 2025, the Scripps Medical Foundation’s Director of Performance Outcomes &amp; Risk Management, Maran Santamana, sent a formal letter. It acknowledged Asbaghi’s concerns, ¨you feel your hip implant contains Bluetooth signals, causing vibration sensations.¨ confirmed that the issues had been investigated through a confidential quality review process, and invoked California Evidence Code §1157, which protects peer-review and quality-improvement materials from disclosure. The letter stated that the review was complete, offered no findings or explanations, and again encouraged him to schedule an in-person orthopedic appointment.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/707/1*y5aS4-N3qHRDpbjB7Vo68Q.png" /></figure><p>The stonewall was now complete. Scripps had acknowledged his concerns enough to open an internal review, yet shielded the outcome behind Evidence Code §1157. Dr. Walker had reviewed the implants remotely in 2025 but would not see him in person. Records appeared and disappeared. Physicians denied seeing him while continuing to order tests. And the vibrations continued.</p><p>Asbaghi was left with the same question he had asked for years: if nothing unusual had been done, why was every attempt to obtain straightforward answers met with evasion, technical barriers, and legal protections?</p><p>None of this is presented as proven fact. I reached out to both Scripps Health and Hooman Asbaghi for comment on these specific allegations. Scripps Health replied that “Due to patient privacy laws we cannot respond to these questions.” Hooman Asbaghi responded that the subject matter is “very sensitive and… could have unpleasant consequences for me and the people I care for,”. What exists is a documented convergence: the exact biomarkers, the Bluetooth telemetry signatures, the RF emissions localized to the implants, the Padtan Elm product catalog, and the timing of the family’s biotech expansion.</p><p>The nightmare had a name now. It was called the Smart Hip.</p><h3><strong>¨Smart¨ Orthopedic Implants And Scripps A W</strong>orld-Renowned Biomedical Powerhouse</h3><p>In La Jolla, California <a href="https://www.scripps.edu/">Scripps Research</a> exceeds through Integrating advanced clinical care with pioneering experimental research, their scientists have driven monumental breakthroughs in immunology, vaccine development and precision digital medicine.</p><blockquote><em>¨Since its founding in 2006 by Scripps Health, STSI has been distinguished by its leadership in translational genomics and for harnessing digital, or wireless, medical technology for health monitoring of individual patients.¨</em></blockquote><p>The anomalies Asbaghi documented align closely with the technical specifications of instrumented “smart” hip prostheses developed in the years immediately preceding his surgeries.</p><p>Research published as early as 2013 outlined complete <a href="https://www.sciencedirect.com/science/article/abs/pii/S0924424713000691">power-management architectures for smart hip implants</a> that harvest energy from multiple internal sources (including piezoelectric transducers and motion), store it in ultracapacitors, and use low-power BLE v4.0 or Texas Instruments SimpliciTI protocols to transmit real-time biomechanical and physiologic data wirelessly. Other studies like <a href="https://iopscience.iop.org/article/10.1088/2516-1091/ac1b7f">Is in vivo sensing in a total hip replacement a possibility</a> noted that RF transceivers operating in the human body’s resonance range (30–400 MHz) are ideal for deep-implant communication because they penetrate tissue most effectively. Vibration-sensing systems were proposed to detect loosening or structural changes: a well-fixed implant behaves as a linear system, while an unstable or sensor-equipped one produces distinct harmonic patterns detectable externally.<br>Smart implants transmit in-vivo data exactly as the Bluetooth network detected on Asbaghi’s phone.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*PSvekQB5OqxjKkevSGxUUg.jpeg" /></figure><p>Peer-reviewed research has explicitly tested Stryker total hip replacement (THR) stems with embedded piezoelectric elements for real-time force measurement — the exact capability required for a “smart hip.” A 2021 <a href="https://www.mdpi.com/1996-1073/14/12/3480">Research Study on Study on Customised Piezoelectric Elements for Energy Harvesting in Total Hip Replacements</a> where researchers cemented “The THR stem (Exeter V40, size 37.5 mm N°3, Stryker) with an integrated piezoelectric element into an artificial femur bone. The experimental setup employed “a uniaxial testing machine to apply the force profiles to the total hip stem, and an oscilloscope to record the output voltage.” This exact Stryker stem design was laboratory-tested with embedded piezoelectric sensors capable of generating measurable voltage outputs from gait forces — the same forces Hooman reported as intense vibrations over his implant sites.</p><p><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6145822/">Smart implants</a> and <a href="https://pubmed.ncbi.nlm.nih.gov/38328442/">Implatable Sensors</a> transmit in-vivo data exactly as the Bluetooth network detected on Asbaghi’s phone. A comprehensive ScienceDirect review <a href="https://www.sciencedirect.com/science/article/pii/S2666351122000080">SMART sensor technology</a> states: “These sensors are devices capable of recognising changes in the physical environment such as strain, temperature, pressure… This in vivo information is then transmitted to the exterior using various systems such as Bluetooth or Radiofrequency (RF) waves. The monitoring computer then analyses the data received and allows clinicians to interpret the changes.” Power-budget challenges for long-term implanted BLE devices are well-documented: “With the new Bluetooth low energy (BLE v.4) technology, it is expected that LR-WPAN protocols can be used in biomedical applications” Peer-reviewed diagrams further illustrate Bluetooth-enabled implantable sensors on orthopedic hardware.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/707/1*_L2sAMRrAbh68NUBBKqd4g.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*XnUvVxWs5DxfIs_FSLtEmQ.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*UorK6Vhq_p5hqbvYVtYn7w.png" /></figure><p>In the book titled “<em>Real-Time Applications of Advanced Electrochemical Sensing Devices</em>”. The research covers biosensors, chemical sensors, IoT, lab-on-a-chip, localization and object tracking, and microelectromechanical systems. This is directly relevant because the technology Hooman documents — implanted electrochemical sensors measuring glucose, testosterone metabolites, PSA, and thyroid markers — is precisely what this field covers. Smart implants can collect data from the patient’s body enabling personalized medicine; four methodologies exist for implant design: non-instrumented passive implants, non-instrumented active implants, instrumented passive implants, and instrumented active implants. The greatest advantage is that such sensors provide data not available through any other means — objective, quantitative, and real-time. And critically from current research: total hip replacement with integrated piezoelectric elements now functions as a self-powered sensor through energy harvesting from low-frequency mechanical movement — the exact gait forces Hooman reports as intense vibrations.</p><p>The technology is not theoretical. It is documented, peer-reviewed, and as Article 3 makes unambiguously clear — it was actively being developed at the very institution where Hooman’s procedures occurred.</p><p>These tech capabilities and connection to Hooman’s health care provider Scripps were not hypothetical. In June 01, 2008, Healio Orthopedics article reported that “all the major orthopedic manufacturers are working on one or more forms of these smart implants,” noting Javad Parvizi, MD — who receives research support from and is a consultant to Stryker — and highlighting vibration detection for loosening and real-time telemetry. The article specifically referenced Scripps Clinic’s work with Drs. Colwell and D’Lima on instrumented implants and directed readers to the <a href="https://orthoload.com/">OrthoLoad</a> database of in-vivo hip forces measured with telemetry-equipped prostheses.</p><p>A Scripps Clinic’s Shiley Center related research article publicly described “<a href="https://www.healio.com/news/orthopedics/20120325/smart-implants-to-provide-biofeedback-measure-joint-loads-detect-infection">smart implants</a>” that could provide biofeedback, measure joint loads in real time, detect infection, and signal problems such as loosening through vibration patterns — exactly the kind of signals Asbaghi has recorded.</p><blockquote>¨This is possible through advances in the fields of nanotechnology, acoustics, computers, microchip technology and other areas, Parvizi explained. Researchers used the technology to incorporate added features into conventional implants that address some of these problems when they arise. One use may be detecting problems like vibration around prostheses, which could signal loosening.¨</blockquote><blockquote>¨According to Darryl D. D’Lima, MD, PhD, available devices can sense temperature, pH, blood glucose levels and record electrical activity of the heart and joint forces. But to be a truly smart implant, it has to have greater capabilities such as the ability to remotely turn on and off, collect data and be reprogrammed, he told Orthopedics Today.¨</blockquote><figure><img alt="" src="https://cdn-images-1.medium.com/max/738/1*aTVuS-tveYiur40pF7WOow.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*E0dMB32MH6m3PKMxg9z34A.png" /></figure><p>Javad Parvizi, MD, who receives research support from and is a consultant to Stryker Orthopedics, stated:</p><blockquote>“All the major orthopedic manufacturers are working on one or more forms of these smart implants,”</blockquote><blockquote>¨Research into smart implants is being conducted worldwide.¨“</blockquote><p>He described surface “smart bombs” that detect infective organisms via pH changes and deliver antibiotics, with animal experiments already showing promise and hopes for clinical reality within one to two years. D<a href="https://www.scripps.org/research/areas-of-research/orthopedic-research/darryl-d-lima-md-phd-director-orthopaedic-research-laboratories">arryl D’Lima, MD, PhD, of Scripps Clinic’s Shiley Center for Orthopaedic Research and Education (SCORE)</a>, was actively researching <a href="http://Implantable Sensor Technology">Implantable Sensor Technology</a> sensor-equipped implants capable of real-time measurements, the sensors are small, simple implantable electronics that are inexpensive and, importantly, require little or no modification to the host implant. The complexity and cost of these systems lie in the external antennae and external electronics. Simple, robust, and inexpensive implantable sensors have clinical applications in fracture healing, spine fusion, and arthroplasty.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*oOl0p_N5pm9xGQVdMmUBIg.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*e544BHVPo_ZJKD4GKAjKbQ.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*l_r-D69G0eBBpWdrLsa2wg.png" /></figure><p>Scripps Clinic’s Shiley Center for Orthopaedic Research and Education (SCORE) was established in 1983 by Clifford Colwell, MD, and has been at the global forefront of instrumented orthopedic research for over two decades. At <a href="https://www.scripps.org/locations/hospitals/scripps-green-hospital">Scripps Green Hospital</a> — the same campus where Asbaghi’s procedures occurred — clinicians and engineers led by Dr. Clifford Colwell developed and implanted the “<a href="https://pubmed.ncbi.nlm.nih.gov/17035919/">e-knee,</a>” The Electronic knee provided wealth of data through an electronic total knee prosthesis containing strain gauges and telemetry circuitry. The very Stryker Trident Acetabular System implanted in Asbaghi lists Clifford W. Colwell, MD, Scripps Clinic, La Jolla, CA as a Study Co-Chair and credits instrumentation specialists in the official Surgical Protocol.</p><p>An instrumented implant containing transducers that measured real-time joint forces during everyday activities. Colwell and D’Lima, SCORE’s Director of Orthopedic Research, have co-led projects on sensor-embedded implants, including force-sensing tibial components and, more recently, an NIH-funded rechargeable “smart shoulder” device designed to track usage, force, acceleration, and range of motion.</p><p>Scripps Health has been at the global forefront of instrumented orthopedic research for over two decades. At Scripps Green Hospital — the same campus where Asbaghi’s procedures occurred — clinicians and engineers led by Dr. Clifford Colwell developed and implanted the “e-knee,” an electronic total knee prosthesis containing strain gauges and telemetry circuitry. The very <a href="https://otcitaly.wordpress.com/wp-content/uploads/2018/01/trident-acetabular-system-surgical-protocol-stryker.pdf">Stryker Trident Acetabular System</a> implanted in Asbaghi lists Clifford W. Colwell, MD, Scripps Clinic, La Jolla, CA as a Study Co-Chair and credits instrumentation specialists in the official Surgical Protocol.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*zi7g902twBVy8sX3RcB8sQ.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*XlNTtgvhNjTxIzp8duy2ew.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*TJewT6KB59h0Hor7B5pxLg.png" /></figure><p>Both of Asbaghi’s total hip replacements were performed at Scripps Green Hospital by Dr. Richard H. Walker, a senior orthopedic surgeon who joined Scripps Clinic in 1983. Walker’s published research interests explicitly include computer-assisted navigation and pressure-sensor applications for total hip and knee replacement. He has co-authored multiple studies with Colwell and D’Lima dating back to the 1990s on hip and knee biomechanics, implant performance, and postoperative outcomes and directly supervises Colwell through the Scripps Clinic Adult Lower Extremity Reconstruction Fellowship program where Clifford Colwell serves as fellowship director.</p><p>During the exact period of Asbaghi’s surgeries (2015–2017), Walker held the highest levels of clinical and administrative authority at Scripps: he served as President of Scripps Clinic Medical Group, Chairman of the Department of Surgery for over 20 years, and chief of staff at Scripps Green Hospital.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*4xAzO7hMlBH-Nmi_ixi0xQ.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*IjooCOCBV3gTG4NrVsTAVQ.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*PcPna9ddB0AswNA4adSgIg.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/912/1*5_9c_9Zutfo5DCAI9e5Q-w.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/899/1*RZbpjhoIUghzO73uWjuXhw.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*n1YFTXFJRLA-yAA_SvIqXA.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/930/1*SViw_Yk6iGquooAVcztRBg.png" /></figure><p>The convergence is striking. The same institution and surgical team that performed Asbaghi’s procedures had spent decades pioneering the precise telemetry, energy-harvesting, vibration-monitoring, and real-time data-collection technologies that match the Bluetooth signatures, RF emissions, and vibration patterns he continues to document. Scripps’ own Bio-Repository &amp; Bio-Informatics Core and its participation in national precision-medicine initiatives provided the infrastructure to collect, analyze, and store such data.</p><p>What remains unexplained is why Asbaghi’s medical records show unconsented laboratory results, missing operative notes, and autonomous Bluetooth activity that precisely mirrors the capabilities Scripps researchers had already demonstrated in instrumented implants — all while senior leadership, including his operating surgeon, held the institutional power to authorize or oversee such systems.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*XEYTy8TYr-_e5Ot2Hyipeg.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*KC2vGKqzmB6TAZboOSwnyg.png" /></figure><h3><strong>Ommid Asbaghi’s Philanthropy Network: Funding the Scripps–UCSD Research Ecosystem</strong></h3><p>His sister Ommid Asbaghi was deeply embedded in San Diego’s high-profile cancer-research philanthropy scene — a network that directly channels millions of dollars into the very institutions where smart-implant research and related immunology work were advancing.</p><p>Public records and news reports show Ommid Asbaghi has served as co-captain of the prominent “Bill’s Angels” team for Padres Pedal the Cause (now the Curebound Cancer Challenge) since at least 2019. She has been a top individual fundraiser, contributing $16,015 in one reported year alongside partner Levant Alkibay, and her team has raised more than $3.7 million lifetime for collaborative cancer research across San Diego institutions. As of 2025, she continues as co-captain and appears in event promotions for the Curebound Cancer Challenge and the Concert for Cures featuring Elton John.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*4QOyqhvoPwdSFG7MIpORFQ.png" /></figure><p>Curebound, formed in 2021 from Padres Pedal the Cause, has raised more than $32.5 million since 2013 (with Padres Pedal alone raising $24 million over 12 years) and explicitly funds research at Scripps Research, UCSD Moores Cancer Center, Salk Institute, Sanford Burnham Prebys, and Rady Children’s Hospital. One hundred percent of donations go directly to life-saving projects. The 2025 Curebound Cancer Challenge alone raised $3.3 million for these institutions, including UCSD Moores and Scripps. This funding flows into the same San Diego ecosystem where Hooman’s surgeries occurred. Scripps Clinic has been the official health-care provider for the San Diego Padres since 1981, with Dr. Richard H. Walker serving as team physician for more than 15 years (including during the Padres’ National League pennant-winning seasons). Dr. Clifford W. Colwell Jr. also held long-standing ties to the organization. The Padres–Scripps partnership and Curebound’s Padres-branded events create a direct philanthropic–institutional bridge.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*vv425kF5YbPttJLxbV5MZA.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/965/1*LF3BLder5UHXiO4DbpyQ5w.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*5urw22tdv-gbkDBPIuDoMg.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*yOkBkL2_4TVXwIHuKTPkZw.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*2BKjvJnhTQArFfFnYF2Y0A.png" /></figure><p>A notable recipient of Curebound funding at UCSD Moores Cancer Center is Dr. Maurizio Zanetti, Director of the Laboratory of Immunology since 1987. Zanetti has received Curebound pilot grants, including the 2022 Cure Prize for research on antitumor B-cell immunity in head and neck cancer patients. His work centers on universal cancer vaccines, leveraging antigenized antibodies and telomerase immune responses — technologies rooted in patents that UCSD released to him following a 1997 scientific-misconduct investigation (in which he was exonerated on major charges but reprimanded on minor policy violations). After the exoneration, UCSD transferred rights to eight of his patents in a 1998 settlement, with two more transferred in 2001. For context on those patent and corporate matters, see the prior investigation: <a href="https://medium.com/@salmeidainvestigates/stolen-legacy-the-hooman-asbaghi-case-how-a-mother-and-sister-allegedly-took-a-25-stake-in-3a8e9bb22727">Stolen Legacy: The Hooman Asbaghi Case</a>.</p><p>Hooman Asbaghi has publicly alleged parallels between his family’s 2013 Padtan Elm asset transfer and patterns in the long-running Gerloni v. Zanetti litigation, Hooman maintains these patterns reflect broader strategies in the San Diego biotech and research community.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*7YYZZiVd-evivjKe76LX_A.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*oh6g95qPAQ13g8evMtTy3Q.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*v8rXDqMQtWB7B3R_4rGlhQ.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/933/1*Ygtand4LxkqTtiepzR4mPg.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*O1NvZRlAL4_TYN7rZDDLQw.png" /></figure><p>The pattern is striking. During the exact period when Hooman’s procedures occurred and smart-implant research was active at Scripps SCORE, his sister was raising substantial funds for the broader San Diego research network that includes both Scripps and UCSD Moores. Public records show no direct personal link between Ommid Asbaghi and the specific orthopedic implant research, yet the documented institutional, philanthropic, and funding overlaps remain unaddressed by the parties involved.</p><p>The documented convergence of family philanthropy, institutional leadership, and precision-medicine funding continues to raise legitimate questions about transparency and data stewardship within the very ecosystem where Hooman’s “smart hip” anomalies first appeared.</p><h3><strong>The Untold Value of One Man’s Data in the Precision-Medicine Revolution</strong></h3><p>Hooman Asbaghi never set out to expose a conspiracy. He simply wanted answers for the vibrations inside his hips, the laboratory results appearing in his MyScripps portal without corresponding visits, and the unrecognized Bluetooth devices that continued to broadcast medical GATT services long after his surgeries. What began as a search for explanation evolved, through documented anomalies and pattern recognition, into a testable theory: that his Stryker hip implants may have been functioning as telemetry-enabled sensors, silently harvesting and transmitting real-time biometric data.</p><p>A comprehensive private investigative report dated January 8, 2026, has now consolidated and analyzed the available evidence from Scripps’ own records. It documents systematic record keeping failures, including the complete absence of 2015 surgical records (operative report, anesthesia notes, implant log, and radiology) due to an EMR migration that Scripps itself admits left historical data unavailable in the current system.</p><p>It identifies an undocumented osteonecrosis diagnosis and provider attribution errors, Endocrine and genetic testing irregularities are also flagged, as is Scripps’ invocation of California Evidence Code §1157 — a statutory shield normally reserved for internal peer-review and risk-management investigations when potential institutional liability is at stake — to protect its review of the implant concerns rather than offering a straightforward clinical explanation.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*TmU3Bb3WjjdHMWYHHTwtMQ.png" /></figure><p>The same MyScripps “Past Visit Details” page provides further evidence of unconsented data importation. Under “Secondary male hypogonadism,” the portal explicitly records “Labs drawn in Iran (patient states it was am): testosterone: 1.89 ng/mL” on September 30, 2016, and states that a DEXA scan “from Iran” confirmed osteoporosis in the radius and lumbar spine. Hooman Asbaghi has confirmed he never underwent any Scripps-related laboratory tests or imaging in Iran. These foreign results were nevertheless integrated into his official U.S. chart and used to justify ongoing treatment decisions.</p><p>Perhaps most striking is the presence in Hooman’s MyScripps record of a sophisticated genetic test for <strong>MTHFR variants</strong> — two common mutations (675C&gt;T and 1298A&gt;C) that affect how the body processes folate, a nutrient essential for DNA repair, hormone regulation, and bone health. The official “Test Details” page and “Result Trends” view show the test was performed on October 13, 2016, with results confirming Hooman is heterozygous for both variants. The sample is listed as processed at the Scripps-affiliated Codex DNA laboratory at 9535 Waples Street in San Diego, and the test was authorized by Dr. Geoffrey Sheean, MD. Hooman Asbaghi states he has never visited that laboratory, never provided a blood sample there, and never met Dr. Sheean. A same-day homocysteine plasma result (also authorized by Dr. Sheean) appears in the same record set.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*mKRngJr8n8XGcrl1uhFBPA.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*YQFIuXwXhD8rietZau7Kgg.png" /></figure><p>The theory that the implants may have functioned as telemetry-enabled sensors remains unproven with respect to the physical hardware itself; no independent forensic extraction or reverse engineering of the devices has yet been performed. Scripps Health has not commented on these specific allegations. Yet the convergence of documentary, timeline, and portal evidence in Scripps’ own records is striking.</p><p>If the theory holds, the scientific and commercial value of that longitudinal dataset would be immense. Meanwhile, the current lawsuit — <em>Asbaghi vs Asbaghi</em>, filed March 17, 2025 in San Diego County Superior Court as a Civil — Personal Injury and Torts matter — remains open. Hooman has repeatedly requested independent forensic analysis of his implants and the full release of missing 2015 and 2017 surgical records.</p><p>The Personalized Medicine Market was valued at USD 530.01 billion in 2023, and is expected to reach USD 1,078.17 trillion by 2032, and grow at a CAGR of 8.21% over the forecast period 2024–2032.</p><p>The healthcare landscape is undergoing a seismic shift, driven by a growing consumer demand for personalized care. This, coupled with a growing distrust of traditional healthcare systems, is fueling a surge in self-service health solutions. According to Abbott Research which indicates a strong patient desire for tailored healthcare at 72% of respondents expressed a need for treatment plans that directly address their specific health conditions and data.</p><p>Personalized medicine is increasingly demanded across a spectrum of medical conditions. The unique biological makeup of each individual necessitates tailored treatments. Chronic diseases like diabetes highlight this need, as blood sugar control and medication efficacy vary widely. Cancer treatment, too, requires a personalized approach, given the diverse genetic makeup of tumors and patient responses to therapies.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*H_jQglaSXVnqfjryq9Z45g.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*j0qGkoTxQPGex5KtEf6ksQ.png" /></figure><p>The global precision-medicine market is projected to grow from approximately $119 billion in 2025 to between $469 billion and $538 billion by 2034–2035, while the broader personalized-medicine sector is forecast to reach $1.2 trillion by 2033. Real-world longitudinal data captured from patients living with implants under everyday conditions — movement, stress, comorbidities, and daily activity — is considered one of the most valuable assets in this ecosystem. Traditional clinical trials provide controlled snapshots. Continuous, real-life biometric streams from smart orthopedic devices offer the kind of “extreme real-world” datasets that AI models, next-generation prosthetics, biosimilar development, and personalized therapies urgently need.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*nl2B8LPOv3f7cPU38yeYUA.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*MAblHeIQ6sgRRK5g5vfmGg.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*aT8tJKattbGXKphZQS5VDA.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*W7mLIucnw39XeB5QLlfnFA.png" /></figure><p>Yet the same technological promise that makes such data valuable also amplifies profound ethical, privacy, and consent challenges. A 2015 review in <a href="http://Cybersecurity vulnerabilities in medical devices">Cybersecurity Vulnerabilities In Medical Devices</a> warned that the shift from isolated to networked medical devices creates systemic cybersecurity vulnerabilities that directly threaten patient safety. Wireless reprogramming, continuous data transmission, and integration with hospital networks expose implants to remote access, data breaches, and unauthorized monitoring. More recent analyses of implantable sensors (Yogev et al., 2023) highlight the persistent gap between research prototypes and clinical adoption, driven in part by unresolved issues of long-term data security, patient control over personal biometric streams, and informed consent for continuous telemetry.</p><p>For additional context on the family biotech and patent matters that intersect with these research networks, see the earlier investigation: <a href="https://medium.com/@salmeidainvestigates/stolen-legacy-the-hooman-asbaghi-case-how-a-mother-and-sister-allegedly-took-a-25-stake-in-3a8e9bb22727">Stolen Legacy: The Hooman Asbaghi Case</a>.</p><p>Letters seeking clarification were sent to Dr. Maurizio Zanetti, UCSD leadership, Scripps Health, and Curebound. UCSD and Dr. Zanetti did not respond. Curebound replied with a standard statement declining comment on allegations involving private individuals, donors, or litigation, while affirming its governance and peer-reviewed grant processes.</p><p>Until independent forensic examination of the implants and full release of the missing surgical records occur, the vibrations continue — and the data, Hooman maintains, keeps flowing. In an era when one patient’s longitudinal biometric stream can help shape therapies for millions, the unresolved questions of consent, privacy, and oversight in smart orthopedic implants remain not only medically significant but ethically urgent.</p><p>Until then, the vibrations continue. And the data, he believes, keeps flowing.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=092ba5c7345e" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Stolen Legacy: The Hooman Asbaghi Case — How a Mother and Sister Allegedly Took a 25% Stake in…]]></title>
            <link>https://medium.com/@salmeidainvestigates/stolen-legacy-the-hooman-asbaghi-case-how-a-mother-and-sister-allegedly-took-a-25-stake-in-3a8e9bb22727?source=rss-940f5cd3834e------2</link>
            <guid isPermaLink="false">https://medium.com/p/3a8e9bb22727</guid>
            <category><![CDATA[pharmaceutical]]></category>
            <category><![CDATA[lawsuit]]></category>
            <category><![CDATA[investigative-journalism]]></category>
            <category><![CDATA[fraud]]></category>
            <category><![CDATA[biotech]]></category>
            <dc:creator><![CDATA[Sofia Almeida]]></dc:creator>
            <pubDate>Wed, 11 Feb 2026 21:41:12 GMT</pubDate>
            <atom:updated>2026-09-24T05:15:17.583Z</atom:updated>
            <content:encoded><![CDATA[<h3>Stolen Legacy: The Hooman Asbaghi Case — How a Mother and Sister Allegedly Took a 25% Stake in Iran’s Billion-Dollar Biotech Empire</h3><p>By : Sofia Almeida। 11 February । 2026</p><p>Hooman Asbaghi is not just another litigant. The San Diego resident is a prolific medical-device inventor. His patents cover safety catheters, retractable needles with damping, and self-sheathing anesthetic syringes. In 2016 he won one of the largest legal-malpractice verdicts in California history: $61.5 million gross against the law firm that botched maintenance fees on his safety-needle patent, costing him lucrative licensing deals</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*s0qPlN0EM6-M5VzfoJ3M2w.png" /><figcaption><em>Asbaghi v. Nydegger, San Diego Superior Court, Case №37–2013–00066639-CU-PN-CTL verdict Oct. 20, 2016</em></figcaption></figure><p>That is the man who now accuses his biological mother, Farideh Kavesh, and sister, Ommid Asbaghi, of misusing a 1999 power of attorney, a forged shareholder resolution, and offshore shells to steal his 25 % stake in a company that grew into a multi-billion-dollar diagnostics and genomics empire. The case is active in San Diego Superior Court. <em>(Asbaghi vs Asbaghi)</em></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*SKASHMPtByvr7HfOv12QRw.png" /><figcaption><em>Asbaghi vs Asbaghi Case №25CU01380C </em>Complaint filed March 17, 2025</figcaption></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*4iLD2k4lEKlHQ8aMrQbRuA.png" /></figure><p><strong>The Foundation of a Conspiracy</strong></p><p>In the early 1990s, Asbaghi made repeated trips from San Diego to Tehran, Iran. Personally introducing the Palmaz-Schatz coronary stent — the world’s first commercially available balloon-expandable stent — in collaboration with Johnson &amp; Johnson and French cardiologist Dr. Bernard Valeix. Valeix visited Iran three times (1991–1993), performing dozens of procedures at Imam Khomeini Medical Center and training local physicians. Dr. Massoud Ghasemi, then a young fellow, stood out; his later career (Scripps Clinic endovascular certification 2003, references to Valeix and Dr. Paul Teirstein) matches the timeline.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/861/1*QgJKsQP9OxKQcxY_biJp2Q.png" /><figcaption>Bernard Valeix, Jean-Leon Guermonprez, and Cass Pinkerton, Indianapolis, USA, 1986</figcaption></figure><p>By 1997, Asbaghi and Ghasemi had helped establish the Madaen Cath Lab, a training center that raised angioplasty standards nationwide.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*J-OvGxjSdHE_Y_Gq93zA1A.png" /><figcaption>Posted on Instagram @ghasemimd.en ¨Where every second matters, and every decision can save a life. This is the Cath Lab — a place where expertise, skill, and technology come together to care for hearts¨</figcaption></figure><p><strong>Padtan Elm: The Company That Vanished</strong></p><p>In 1995 Hooman claims he co-founded Padtan Elm Pharmaceutical in Tehran, Iran. The company specialized in high-sensitivity ELISA diagnostic platforms and immunoassay technologies. Padtan Elm was the first manufacturer of ELISA diagnostic kits in Iran. The company had grown to produce over 30 diagnostic products, making it one of Iran’s largest suppliers of ELISA kits.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/448/1*VKeWAJPmKbL_knDXnLFIvA.jpeg" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*zch4uenMXplW9NcUNq_xJQ.png" /><figcaption>Company profile at <a href="http://www.ttnet.net/">www.ttnet.net</a> — Padtan Elm Company, Iran Manufacture</figcaption></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*0ur9mYudr20905cpg4Ijtg.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/903/1*8IGPYvs13SLtT1BATGaTLA.png" /><figcaption>Nargues Djavad listed as Manager of Padtan Elm Co <strong>— </strong><em>Wiley publications noting a Padtan Elm, P</em>ublished: 25 May 2020</figcaption></figure><p>Its reagents and kits were later cited in peer-reviewed international studies alongside suppliers such as Sigma, Bio-Rad, Merck and Hi-Media.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*LhckcIk1Lg_zvyWSxhRx7A.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*d3zeat93iyOVih9Ao_rrQA.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*e0NfsmZIx_3G4lcCLdEy4A.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*Cj7P4h2-7bOQ3w8inx8QAw.png" /></figure><p>Iran’s official corporate registry <em>(Rasmio, Profile)</em> records Padtan Elm’s founding on 7 January 1997 as a private joint-stock company. The registry lists four founding shareholders, each with 250 of 1,000 shares (25%):</p><ul><li>Hooman Ali Tabatabai Asbaghi</li><li>Farideh Kavesh</li><li>Nargues Djavad</li><li>Alireza Amiri Gharagozlou</li></ul><p>Multiple subsequent filings (1997 through the early 2000s) continue to show Hooman as a shareholder and board member in the company’s early years. Farideh Kavesh repeatedly appears as Chair or Vice-Chair.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/839/1*ibS8cPriqC7YLrvxlIgFYA.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*g-X9udZWz5XFXtoa-56k_w.png" /><figcaption>Google search of ¨Hooman Asbaghi and Padtan Elm¨ results — Rasmio profile (written in farci) no longer shows up in results but was saved as PDF by Mr. Asbaghi</figcaption></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*TxcJ6jnrgUotPTkk7pqwOQ.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*40oNJGjEeToIgTBVJBktEQ.png" /></figure><p>By the early 2000s the company ran a professional website offering OEM ELISA kit manufacturing: antibody conjugation, microplate coating, lyophilization, and custom IVD assay development.</p><p>Today, the domain padtan.com no longer resolves to any website. Direct attempts to visit it return no content at all — the domain is unregistered or expired, with nothing served. Yet the company’s LinkedIn profile, which remains publicly active and describes Padtan Elm as a Tehran-based medical-device firm founded in 1995, continues to list<a href="http://www.padtan.com/"> www.padtan.com</a> as its official website. That link now leads nowhere.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*HRQ9B-lLtyvorP42276H0A.png" /><figcaption>Padtan Elm´s LinkedIn profile</figcaption></figure><p>This disappearance of the primary online presence — combined with an outdated but still-prominent professional listing and the effective erasure of the site’s historical content — leaves only scattered peer-reviewed citations as surviving evidence of Padtan Elm’s former commercial operations and OEM capabilities.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/923/1*LPVgCRl5Bm70Xm8Y9UDAiQ.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*2HluWIC5y31bghd_aETkcg.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*XToJaPzQEJiFJBwHjX-w3g.png" /><figcaption>Wayback machine search for Padtan.com captures expanding from 2002–2024</figcaption></figure><p><strong>The Sanctions Window + Iran’s Pharma Boom</strong></p><p>President Clinton’s Executive Orders 12957 (March 1995) and 12959 (May 1995) banned almost all U.S. trade and investment with Iran. Food, medicine, and certain medical technologies remained licensable — the narrow window Asbaghi used to introduce advanced stents and diagnostic platforms.</p><p>At exactly that moment, Iran’s pharmaceutical market exploded. A 2020 peer-reviewed study in <em>DARU Journal of Pharmaceutical Sciences</em> documented:</p><ul><li>1997–2010: annual sales-value growth of <strong>28.38%</strong> (while population grew only 1.53% per year)</li><li>Domestic production: <strong>+1,018%</strong> total</li><li>Imports: <strong>+4,373%</strong> total</li><li>Per-capita drug spend: <strong>$2.28 → $34.43</strong></li></ul><p>A 2020 analysis in the <em>Journal of Pharmaceutical Policy and Practice</em> added that the market reached <strong>$4.71 billion</strong> in 2012, immediately before the next wave of intensified sanctions.</p><p>Padtan Elm’s high-sensitivity ELISA kits, OEM manufacturing expertise, and emerging biopharma capabilities were perfectly positioned to ride — and help drive — this historic boom.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*OJnR995y0und89arDqRW_g.png" /><figcaption>¨The impact of sanction and healthcare system reform on the healthcare performance and pharmaceutical market in Iran; 2001–2016¨</figcaption></figure><p><strong>The 1999 Power of Attorney</strong></p><p>In 1999, while in Tehran, Hooman executed a full power of attorney granting his mother, Farideh Kavesh, complete authority over all his Iranian affairs . He then returned to the United States to concentrate on his own medical-device inventions, which produced a $1 million licensing deal with Nipro, which led to the years later, $61.5 million legal-malpractice verdict against the firm that allowed one of his safety-needle patents to lapse see in (<em>Asbaghi v. Nydegger).</em></p><p>Hooman believed the POA was a protective measure that would allow him to focus stateside while his mother safeguarded his Iranian interests. Court filings now allege it became the central legal instrument that enabled his eventual dispossession.</p><p>That same mid-1990s period also saw the creation of parallel U.S. structures. Hooman states that, at his mother’s suggestion, he agreed to bring his sister Ommid into operations and even proposed that Ommid and his then-wife Carolin Botzenhardt form a company — Ayla Medical — to manage U.S.-side technology transfers.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/833/1*XHlUFMESBQVcntu6bfTm5w.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/830/1*CxFlV_Qv8QtFREJN8rEklg.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/833/1*_F2qKDZw_pYkOwBuj2rUNQ.png" /><figcaption>CorporationWiki, April 4, 2022 (document #199619410017).</figcaption></figure><p>Instead, California Secretary of State records confirm that Trans In’Tech, LLC was incorporated on 12 July 1996.</p><p>A public Network Visualizer explicitly shows both Farideh Kavesh and Ommid Asbaghi directly connected to the entity — Ommid listed as manager/key principal, with Farideh also formally tied to it. The company is currently marked as “Active.”</p><p>Its described activities match precisely the U.S.-side technology-transfer role Hooman says was supposed to be handled through Ayla Medical.</p><p>Hooman alleges this became the “parallel company” created — at his mother Farideh Kavesh’s suggestion and with her direct participation — to bypass him, laying the early groundwork for the strategy that culminated in the 2013 asset transfer.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/851/1*1u_Q7dAmZmEtETac-T-fCQ.png" /><figcaption>Trans In’tech, LLC lists Ommid Asbaghi as sole key principal and activities in medical research, diagnostic equipment, and scientific equipment wholesaling.</figcaption></figure><p><strong>The La Jolla Network: Interconnected Professional and Social Circles in San Diego</strong></p><p>A documented web of relationships among Hooman Asbaghi’s former wife, his sister Ommid S. Asbaghi, and key figures in Iranian-American professional and philanthropic circles in La Jolla has been cited in the allegations.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*al8zaDuEFWWMfHSpHI3CLA.png" /><figcaption>Hooman Asbaghi´s and Carolin Botzenhardt marriage certificate is listed on Archives.com</figcaption></figure><p><strong>Carolin Botzenhardt</strong> maintained a long career in private wealth management during the period of the alleged asset transfers and revenue rerouting:</p><ul><li>Deutsche Bank Securities Inc. (October 2003 — March 2017)</li><li>Wells Fargo Clearing Services (May 2017 — June 2022)</li><li>UBS Financial Services Inc., La Jolla office — Senior Vice President, Private Wealth Management (June 2022 — present)</li></ul><p>Her Deutsche Bank tenure coincided with the bank’s admitted processing of over $10.86 billion in non-transparent U.S. dollar clearing transactions for sanctioned Iranian and other entities (1999–2006), for which the bank paid a $258 million penalty (NYDFS/Federal Reserve, 2015).</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*iAgfZs_Oh25Xuai-NrS7BQ.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*-LEw7HM7VxqXMkhxQe-06w.png" /><figcaption>¨Carolin Botzenhardt, vice president of Deutsche Bank Private Wealth Management in Costa Mesa¨ Article´s published by Los Angeles times June 22, 2005 — AUG 08, 2022 By InvestmentNew</figcaption></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*q7ssF_Kb6NRUvrpyZUfUvw.png" /></figure><p>Carolin served on the Board of Trustees of the Museum of Contemporary Art San Diego (MCASD) for the 2009–2010 term (announced September 2009). Public donor records and photographs show her continuing social and philanthropic overlap with Ommid Asbaghi and Sherry Bahrambeygui, including joint appearances at La Jolla gallery events and shared donor listings.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*EPagS87NgmzBEZD_fRZL5Q.png" /><figcaption>The San Diego Tribune The Board of the Museum of Contemporary Art San Diego names Carolin Botzenhard</figcaption></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*6kqHZiH68bG_6vPzJ7FKUw.png" /><figcaption>Pictured — Pouneh Harandy, Sherry Bahrambeygui, Carolin Botzenhardt and Ommid Asbaghi — 2022</figcaption></figure><p>Sherry Bahrambeygui (Ommid Asbaghi’s longtime friend, attorney, and business associate) is a prominent figure in the same circles:</p><ul><li>Former Chief Executive Officer, PriceSmart, Inc. (NASDAQ: PSMT; interim CEO 2018, full CEO 2019–February 2023)</li><li>Longtime director and executive roles at PriceSmart and affiliated entities</li><li>Current board member of the Public Affairs Alliance of Iranian Americans (PAAIA)</li><li>Trustee of the UC San Diego Foundation</li></ul><p>Sherry has served on the PAAIA board alongside honorees and leaders tied to the organization’s founding network. She and Ommid Asbaghi appear together as donors to Curebound (August 2025 records: Ommid $50, Sherry $5,000 on the same day). Photographs document the three women together at social and cultural events in La Jolla.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*IGhWLwce4qKxDDO8iduvsw.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*tatmfygMfdcT2eyGmKzNAw.png" /><figcaption>Ommid Asbaghi and Sherry Bahrambeygui Fundraising for Curebound August 13, 2025 — Sherry Bahrambeygui Museum of Contemporary Art</figcaption></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*P-12Bc_P-je6xAkqWNeOxg.png" /><figcaption>Ommid Asbaghi and Carolin Botzenhard listed as host committee members for Curebound 2022</figcaption></figure><p><strong>Babak Hoghooghi</strong>, a recognized expert in U.S. economic sanctions, OFAC compliance, export controls, and Iran-related matters, provides the organizational link:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*XC1ySUVQIJVysRPhI-DFEA.png" /></figure><ul><li>Founding Board Member and first President, Iranian American Bar Association (IABA, 2001–2005)</li><li>Founding Executive Director, Public Affairs Alliance of Iranian Americans (PAAIA, 2007–2010)</li><li>Managing Partner, Berliner Corcoran &amp; Rowe LLP (Washington, D.C.)</li></ul><p>According to Hooman Asbaghi, Babak was introduced to him by a mutual friend to investigate the alleged theft of his Padtan Elm shares. Babak allegedly conditioned his involvement on Hooman first depositing $400,000 into an escrow account for a third-party investigation, to be issued in quarterly reports. Hooman further alleges that Babak ultimately delivered approximately 300 pages of reports that were false or misleading and served to conceal the share theft and asset stripping. Hooman has filed a formal disciplinary complaint against Hoghooghi with the D.C. Bar alleging professional misconduct.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*YPTRqBhz7OlrefK63JJ42A.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*H8rik4kiWE0-X4R5D434Jw.png" /><figcaption>Babak Hoghooghi PAAIA Executive director — Sherry Bahrambeygui PAAIA board member</figcaption></figure><p>These verified professional histories and documented social overlaps illustrate a tightly interconnected La Jolla–based Iranian-American network spanning high-level banking, corporate leadership, sanctions law, and elite philanthropy.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*icWLGP46gGux4N1elgjWSQ.png" /><figcaption>Office of Disciplinary Counsel Email Response to Hooman Asbaghi regarding a disciplinary complaint against Babak Hoghooghi</figcaption></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*yj2DxCCo6w-nT4GUahBGsw.png" /><figcaption>Unknown, Ommid Asbaghi, Sherry Bahrambeygui, Unknown and Pouneh Harandy — Picture taken for Sherry Bahrambeygui birthday April 2019</figcaption></figure><p><strong>The 20-Year Patent Delay: Zanetti v. Gerloni and the Alleged Parallel U.S. Structures</strong></p><p>A California Court of Appeal opinion filed February 1, 2013 — exactly 18 days after the alleged January 14, 2013 Padtan Elm asset transfer — finally ended the long-running case Mara Gerloni v. Maurizio Zanetti (D059695).</p><p>The court affirmed summary judgment for Zanetti on all claims (misappropriation of corporate opportunity, breach of fiduciary duty, breach of contract, fraud, constructive trust). The key findings:</p><ul><li>Gerloni claimed Zanetti promised her 6.5% ownership (650,000 shares) and profit sharing. In a November 2008 declaration she swore he told her “we were going to be billionaires” and that she was “a 6.5% owner of Transgenix.”</li><li>One month later in deposition she repeatedly testified: “I don’t remember” any specific promise of ownership, financial benefit, or that Transgenix owned the patents.</li><li>The court ruled: “This is an egregious case of pleadings grossly contradicting the testimony of plaintiff provided under oath.” Her declaration was disregarded.</li><li>She never paid for the shares, never executed a shareholder agreement, and the court held she lacked standingbecause all remaining claims were derivative and she was not a shareholder.</li><li>Zanetti had sold the empty Transgenix shell corporation to Cosmo S.p.A. for a net $18,000 (after routing millions in licensing revenue through offshore holding companies).</li></ul><p>The controversy around Zanetti’s foundational transgenesis and antigenized-antibody patents actually began much earlier. In 1993 Paolo del Guercio, a junior researcher in Zanetti’s UCSD AIDS lab, accused him of fabricating research results and violating university policies on the use of animals in research, human experiments, and biosafety standards. A February 13, 1997 Nature article reported that UCSD committees found evidence of fabricated data in published articles and possible suppression of an HIV experiment to secure NIH grants. Federal authorities became involved. Zanetti denied all misconduct. The tenure committee ultimately exonerated him, determining that his accuser had lied. In the 1998 settlement that followed, UCSD released the key patents to him.</p><p>Hooman Asbaghi has long alleged that this litigation was strategically prolonged to shield Zanetti’s foundational transgenesis and antigenized-antibody patents, giving Padtan Elm / Iranome a competitive window during Iran’s biotech expansion.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*ogxxRacwjbolWF1IfVcrWA.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*uFXX5g4b5fv2UTcaVpZzew.png" /><figcaption>Mara Gerloni linkedin profile — Maurizio Zanetti Ocean Therapeutics profile</figcaption></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/992/1*jQ3IDzkNSBh2ZEe8xNoZkw.png" /><figcaption>Gerloni v. Zanetti (3:07-cv-02366) District Court, S.D. California</figcaption></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*oh6g95qPAQ13g8evMtTy3Q.png" /><figcaption>One of Zanetti´s patent´s found at patents.justia.com/inventor/maurizio-zanetti</figcaption></figure><p>The specific allegations of coordination, interference, or concealment remain unproven and we hope will be addressed through discovery and testimony in San Diego Superior Court.</p><p>What´s proven by public records?</p><ul><li>Patents entangled in legal disputes from 1993–2013</li><li>In a 1998 settlement UCSD released the patents to Zanetti ¨Universal Cancer Vaccine¨</li><li>Gerloni’s 2006–2013 lawsuit kept the patents/Transgenix in limbo until 18 days after the Padtan Elm transfer</li><li>Gerloni’s deposition directly contradicted her declaratoin on ownership promises and the court ruled she lacked standing as a non-shareholder.</li><li>Transgenix shell sold for net $18,000 after millions were routed through offshore structures.</li><li>Trans In’Tech, LLC incorporation 1996</li><li>Zanetti’s 1993 UCSD fraud accusation, exoneration, and 1998 patent release</li><li>Mara Gerloni became CEO of the Cosmo shell entity</li></ul><p>What´s still allegation and for discovery?</p><ul><li>Coordination between Ommid, Zanetti, and Gerloni to prolong the case</li><li>Use of the litigation as a deliberate shield for Iranian-side development</li><li>Trans In’Tech as the parallel bypass company tied to the broader alleged scheme</li></ul><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*JDbE6p-CzbEZx4TSz8oDDw.png" /><figcaption>NATURE J VOL385 113 FEBRUARY 1997</figcaption></figure><p><strong>The 2013 Transfer — The Moment Everything Vanished</strong></p><p>On 14 January 2013, at Padtan Elm’s Tehran office, a shareholder meeting took place without Asbaghi present.</p><p>Kianoush Behlouli — Principal Inspector of Padtan Elm (2010–2012) — later wrote directly to Asbaghi in a signed letter written in farci:</p><blockquote>“In the meeting dated 14 January 2013, a minutes was prepared <strong>without your presence</strong>… signed by the major shareholders. I asked your mother several times for your phone number. She stated that she holds your full power of attorney… Since your sister Ommid was managing the related affairs, and I knew you had <strong>no knowledge</strong> of these events… Ms. Kavesh removed me from my position as Principal Inspector so that they could fully implement their plans.”<br>(Verified Translation)</blockquote><p>The resolution transferred Asbaghi’s 250 shares to Farideh Kavesh and shifted all assets to Padtan Teb “for export purposes.” Padtan Elm was left empty.</p><p>Padtan Teb claims a 1990 founding but had no online presence before June 23, 2013</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*O4Hzl_ieIqd1obCtMxCkTA.png" /><figcaption>web.archive.org search for Padtanteb.ir</figcaption></figure><p>The asset transfer happened six months before key provisions of the Iran Freedom and Counter-Proliferation Act (IFCA) took effect on 1 July 2013, tightening secondary sanctions and freezing many banking channels for Iranian pharma imports. The sector faced documented shortages of APIs, raw materials, and finished drugs. The “export vehicle” rationale was plausible on paper — but Asbaghi alleges it was cover for stripping him of his stake just as the company’s value was about to surge.</p><p>The timing also aligns with the final dismissal of the Zanetti v. Gerloni case — 18 days after the transfer. Asbaghi claims this cleared long-blocked transgenesis and antigenized-antibody patents, enabling the family-controlled Pathobiology Laboratory Centers / Iranome project to enter its public sequencing phase in 2014 and capitalize on the prepared genomic dataset.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/773/1*n8jlhsKLXvCoFKlEHXCdrg.png" /><figcaption>Pathobiology Laboratory Center Google Street photo</figcaption></figure><p>Pathobiology Laboratory Centers (PLC) of Tehran have been instrumental in the Iranome genomics project, providing comprehensive pathology and genomic analysis that helped map genetic variations specific to the Iranian population. PLC is described in public materials as one of Iran’s largest, most advanced, and best-equipped diagnostic facilities, with WHO recognition for excellence in clinical pathology and related testing.</p><p>According to Mr. Asbaghi, Farideh Kavesh serves as Chairperson of the Board of the Pathobiology Laboratory Centers. The 2025 complaint states that her wealth originates from pharmaceutical and genomic advancements enabled by the Human Genome Project, with key collaborations conducted through Padtan Elm and its biopharmaceutical arm, involving companies such as Roche, Merck, Sigma, BioMérieux, and Thermo Fisher. It explicitly links PLC to these revenue-generating activities, including biosimilar development, patents, and confidential revenue-sharing agreements under NDAs.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*EbuwgDxR9ITFGUutg3UsEQ.png" /><figcaption>Dr. Richard A Harvill, President of the University of Arizona pictured with Farideh Kavesh in 1951</figcaption></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*ob2xzBxpgRbQwM2t749kag.png" /><figcaption>International Students group picture listing Farideh Kavesh 1952 (middle of row 1)</figcaption></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*hT7R7a-0rKfU02mIgoDxhg.png" /><figcaption>Marriage Certifcate Records of Ahmad Ali Asbaghi (Hooman´s father) and Farideh Kavesh (Hooman´s Mother)</figcaption></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/905/1*NXloJ0tsTDApV2VqaRXPEQ.png" /><figcaption>Farideh Kavesh 2006</figcaption></figure><p>Just three months after the January 2013 asset transfer, Thermo Fisher Scientific announced its $13.6 billion acquisition of Life Technologies (Invitrogen + Applied Biosystems) on 15 April 2013. The deal closed in February 2014 and instantly made Thermo the dominant player in molecular diagnostics, ELISA/immunoassay reagents, PCR, NGS library prep, custom assay development, and bioprocessing.</p><p>Additional 2015 tuck-ins (including Advanced Scientifics) further ramped up demand for outsourced, high-quality OEM manufacturing — exactly the services Padtan Elm had been quietly perfecting.</p><p>Padtan Elm’s pre-2013 website and corporate filings advertised:</p><ul><li>Custom IVD assay development from R&amp;D to production</li><li>Antibody purification, HRP conjugation</li><li>Microplate coating</li><li>Professional lyophilization</li><li>OEM contract manufacturing</li></ul><p>All under ISO 13485:2012 and ISO 9001:2015 certification — standards that match the quality systems Thermo requires from its private-label partners.</p><p>Asbaghi alleges that undisclosed OEM agreements with Thermo (via Invitrogen/Life Tech channels) were already in place before the transfer, and that the revenues from scaling those deals were rerouted after his 25% stake was stripped.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*f5V2y0IDYWUKHyR2wkjSIQ.png" /><figcaption>Thermo Fisher Scientific OEM requiremens listed on thermofisher.com</figcaption></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*T9Wqnti5BaUdacymY6S4ZA.png" /><figcaption>Thermofisher Invitrogen Immunoassays from thermofisher.com</figcaption></figure><p>The digital footprint vanished. The money trail — according to the complaint — went offshore. The patents were freed. Iranome moved forward.</p><p>This is the moment the alleged value transfer becomes visible on the global stage.</p><p>This single January 2013 meeting is now the hinge on which the entire lawsuit turns.</p><p><strong>Padtan Elm’s Billion-Dollar Bright Future: Genomics, Iranome, Global Deals, and the Shell Structures</strong></p><p>By the late 2000s, Padtan Elm had evolved far beyond its original ELISA diagnostic kits. Its biopharmaceutical capabilities grew rapidly during Iran’s 1997–2013 pharmaceutical boom, positioning the company for the next frontier: genomics and precision medicine.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/599/1*e4CvB6NKQsrAYRsFAc64NA.jpeg" /><figcaption>Images from Padtan.com before erasure</figcaption></figure><p>The key catalyst was <strong>Iranome</strong>, a major population-specific genomic project. Launched in the mid-2010s through collaboration between Iranian researchers and the University of Toronto, Iranome performed whole-exome sequencing on 800 individuals from eight major Iranian ethnic groups. The resulting database catalogued 1.57 million genetic variants — including more than 308,000 novel ones — filling a critical gap in global genomic data for Middle Eastern populations. This resource has direct applications in personalized medicine: improved diagnostics for prevalent conditions like thalassemia and cardiovascular disease, pharmacogenomics to predict drug responses, and the foundation for AI-driven analysis of unified genomic and clinical data.</p><p>Hooman Asbaghi alleges that Padtan Elm’s advanced OEM manufacturing, reagent platforms, and ties to Farideh Kavesh’s Pathobiology Laboratory Centers provided essential infrastructure and sample-handling expertise that supported this genomic work and its commercialization.</p><p>To monetize these assets amid sanctions, the network allegedly relied on a series of shell entities:</p><ul><li>Padtan Teb</li><li>PTELM</li><li>Padza Padtan Company</li></ul><figure><img alt="" src="https://cdn-images-1.medium.com/max/784/1*Ayd9fVDoxwPRkSGe6M-fUQ.png" /><figcaption>Padza Padtan Company — Logo matches Padtan Elms logo</figcaption></figure><p>The clearest documented example is the March 2016 licensing agreement between PTELM and Roche Sequencing. The contract granted Roche rights to DNA-amplification technology in exchange for:</p><ul><li>Upfront payment: CHF 132,382,499.93 (approximately $132–140 million at the time)</li><li>42% royalty on net sales</li><li>Additional milestone payments, exclusivity, and confidentiality provisions</li></ul><p>Signed by Meisam Asgari (PTELM CTO) and Leonardo Lauciello (Roche), the deal sits in the evidentiary record of the 2025 complaint.</p><p>Asbaghi alleges that revenues from the Roche deal, Thermo Fisher-related work and broader genomics partnerships — potentially reaching billions or more when factoring in the Iranome/AI multiplier — were routed through offshore accounts to which he was denied access.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*Wahcj56AJkZ2vhtWaPO0Pw.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*xq6u3cO57dDYeipKfnB89A.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*JP-Lk0755yVYdoRnsRHqYA.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*8aH9b8H1bb4cpvKVSo5aHA.png" /><figcaption>PTELM — Roche Pharmaceutical Licensing Agreement displayed in court documents</figcaption></figure><p><strong>Where the Story Stands</strong></p><p>There is not yet a judicial finding of liability. What exists is a compelling, interlocking chain of public records: corporate registries confirming the founding and 25 % shareholding, a contemporaneous eyewitness letter from the company inspector, the signed Roche licensing contract with the exact figures Hooman has long claimed, peer-reviewed citations that survived the digital erasure, Wayback Machine captures showing the website’s disappearance, and now an active sworn complaint in California superior court.</p><p>Investigations do not begin with proof of guilt. They begin with leads, patterns, connections, documents, and verifiable public records that raise serious questions — and in this story there is no shortage of those things.</p><p>The case (<em>Asbaghi v. Asbaghi)</em> is ongoing. Discovery, forensic accounting, expert testimony, and cross-examination will determine whether the documented financial flows, corporate shells, erased digital presence, and overlapping networks amount to legitimate business restructuring under sanctions pressure — or something far more serious.</p><p>The inventor who once helped ignite Iran’s biotech explosion, personally introduced the Palmaz-Schatz stent to the country, and whose alleged contributions aligned with major global life-sciences deals now sits in San Diego. His company’s website is parked, his royalties are allegedly rerouted, and his health is allegedly damaged by the very technology he helped create.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/263/1*T9bR9YAmnIpzSqViVG6x4Q.jpeg" /><figcaption>Hooman Asbaghi — CEO at HBA Medical Group, CEO at MMI Medical</figcaption></figure><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=3a8e9bb22727" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>